Canada

Population 2018 37 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>2.1 (1.8–2.4)</td>
<td>5.6 (4.8–6.4)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.086 (0.028–0.18)</td>
<td>0.23 (0.08–0.47)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0.025 (0.012–0.044)</td>
<td>0.07 (0.03–0.12)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>0.12 (0.12–0.12)</td>
<td>0.33 (0.33–0.33)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.013 (&lt;0.01–0.028)</td>
<td>0.04 (0.01–0.08)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 0.82% (0.33–1.7)
- Previously treated cases: 6.3% (1.7–15)

TB case notifications, 2018

- Total new and relapse: 1 796
  - % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status: 67%
  - % pulmonary: 68%
  - % bacteriologically confirmed**: 89%
  - % children aged 0-14 years: 5%
  - % women: 44%
  - % men: 51%
- Total cases notified: 1 796

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 7% (6–8)
- TB/HIV care in new and relapse TB patients, 2018
  - Number (%)
  - Patients with known HIV status who are HIV-positive: 42 3%
    - on antiretroviral therapy

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**
  - New cases
  - Previously treated cases

Laboratory-confirmed cases*

- MDR/RR-TB: 25, XDR-TB: 1
- Patients started on treatment**
  - MDR/RR-TB: 18
  - XDR-TB:

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 80% 1 831
- Previously treated cases, excluding relapse, registered in 2017
- HIV-positive TB cases registered in 2017: 75% 28
- MDR/RR-TB cases started on second-line treatment in 2016
- XDR-TB cases started on second-line treatment in 2016

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions)

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2020-04-12 Data: www.who.int/tb/data